Holen Sie sich die Stockscreener-App
22.52
1.49%
0.33
Schlusskurs vom Vortag:
$22.19
Offen:
$22.26
24-Stunden-Volumen:
720.85K
Relative Volume:
0.57
Marktkapitalisierung:
$2.78B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
19.08
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
+4.99%
1M Leistung:
+3.26%
6M Leistung:
+6.43%
1J Leistung:
+40.75%
1-Tages-Spanne:
$22.14
$22.67
1-Wochen-Bereich:
$21.04
$23.27
52-Wochen-Spanne:
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.52 | 2.78B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - Insider Monkey
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance
Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com
Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire
First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - Quantisnow
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN
Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN
Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st
CPRX stock soars to all-time high of $24.8 amid robust growth - Investing.com
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Option Exercise |
2.24 |
44,904 |
100,585 |
113,777 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 06 '25 |
Sale |
21.67 |
180,096 |
3,902,680 |
68,873 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Sale |
22.09 |
44,904 |
991,929 |
68,873 |
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):